EUVIMEDEUVIMED entdecken
Crossref

PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection

Yue Song, Jingshi Wang, Yini Wang, Lin Wu, Yahong You, Deli Song, Leilei Chen, Gaungqiang Meng, Xiaodan He, Tingting Cui, Xiaodi Wang, Qingxia Yin und 1 weitere

Clinical Microbiology and Infection · 2023-06 · 29 (6) · 796.e7-796.e13

DOI: 10.1016/j.cmi.2023.01.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2023-06. Verfasst von Yue Song und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Beijing Municipal Science and Technology Commission, National Natural Science Foundation of China, Beijing Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Chronic active Epstein-Barr virus infection (CAEBV) is a prototype of EBV-associated T-or NK-cell lymphoproliferative diseases. It is a disease with poor outcome. Almost all current therapies are ineffective except of allogeneic hematopoietic stem cell transplantation. METHODS: We investigated the efficacy and safety of programmed death 1 (PD-1) blockade (Sintilimab), combined with lenalidomide, which is an immunomodulatory drug, in an open-label, single-center, prospective study involving CAEBV patients. PD1 blockade 2mg/kg was given every two weeks by intravenous infusion on day 1, and lenalidomide 5mg (age

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsHumansAdolescentHerpesvirus 4, HumanLenalidomideProgrammed Cell Death 1 ReceptorLeukocytes, MononuclearDNA Copy Number VariationsProspective StudiesChronic Disease

Stichwörter der Autor:innen

BlockadeClinical trialEpstein-Barr virusLenalidomideLymphoproliferative diseasePD-1PathogenesisPredictive valve

Substanzen

LenalidomideProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Electronic address: wangzhao@ccmu.edu.cn.

Förderung

  • Beijing Municipal Science and Technology Commission
  • National Natural Science Foundation of China
  • Beijing Municipal Health Commission

Zitieren

APA

Song, Y., Wang, J., Wang, Y., Wu, L., You, Y., Song, D., Chen, L., Meng, G., He, X., Cui, T., Wang, X., Yin, Q., & Wang, Z. (2023). PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection. Clinical Microbiology and Infection, 29(6), 796.e7-796.e13. https://doi.org/10.1016/j.cmi.2023.01.017

Vancouver

Song Y, Wang J, Wang Y, Wu L, You Y, Song D, et al. PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection. Clinical Microbiology and Infection. 2023;29(6):796.e7-796.e13. doi:10.1016/j.cmi.2023.01.017

BibTeX
@article{Song2023,
  author = {Song, Yue and Wang, Jingshi and Wang, Yini and Wu, Lin and You, Yahong and Song, Deli and Chen, Leilei and Meng, Gaungqiang and He, Xiaodan and Cui, Tingting and Wang, Xiaodi and Yin, Qingxia and Wang, Zhao},
  title = {PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection},
  journal = {Clinical Microbiology and Infection},
  year = {2023},
  volume = {29},
  number = {6},
  pages = {796.e7--796.e13},
  doi = {10.1016/j.cmi.2023.01.017}
}
Kostenlos starten →